Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Blood. 2013 Jun 6;121(23):4778-81. doi: 10.1182/blood-2013-01-478891. Epub 2013 Apr 16.


Standardized response criteria to interpret and compare clinical trials are needed for approval of new therapeutic agents by regulatory agencies. The European LeukemiaNet (ELN) response criteria for essential thrombocythemia (ET) and polycythemia vera (PV) issued in 2009 have been widely adopted as end points in a number of recent clinical trials. However, evidence exists that they do not predict response or provide clinically relevant measures of benefit for the patients. This article presents revised recommendations for assessing response in ET and PV provided by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment. New definitions of complete and partial remission incorporate clinical, hematological, and histological response assessments that include a standardized symptom assessment form and consider absence of disease progression and vascular events. We anticipate that these criteria will be adopted widely to facilitate the development of new and more effective therapies for ET and PV.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Consensus*
  • Humans
  • International Agencies / standards*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Polycythemia Vera / drug therapy*
  • Polycythemia Vera / mortality
  • Practice Guidelines as Topic / standards*
  • Societies, Medical
  • Thrombocythemia, Essential / drug therapy*
  • Thrombocythemia, Essential / mortality


  • Platelet Aggregation Inhibitors